Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) (CANTOS)
Main Study (CACZ885M2301): The purpose of the pivotal phase of this trial was to test the hypothesis that canakinumab treatment of patients with myocardial infarction (MI) at least one month prior to study entry and elevated hsCRP could prevent recurrent cardiovascular events.
11.04.2011 – 14.04.2019 EMRAH YEŞİL, İSMAİL TÜRKAY ÖZCAN
A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS)
The purpose of this study is to compare the effect of ticagrelor versus placebo in patients with Type 2 Diabetes Mellitus.
10.02.2014 – 25.01.2019 EMRAH YEŞİL, İSMAİL TÜRKAY ÖZCAN
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF (RELAX-AHF-2)
The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.
02.10.2013 – 01.02.2017 EMRAH YEŞİL, İSMAİL TÜRKAY ÖZCAN
Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients (TITRATION)
The purpose of this study is to assess the safety and tolerability of initiating LCZ696 in heart failure patients with reduced ejection fraction (HF-rEF) using conservative (reaching target dose over 6 weeks) and condensed (reaching target dose over 3 weeks) up-titration regimens
01.11.2013 – 29.08.2014 EMRAH YEŞİL, İSMAİL TÜRKAY ÖZCAN